Drug intelligence / Profile preview

miR-25 lentiviral vector

Development stage
Preclinical
Lead developer
Chinese Academy of Medical Sciences
Modality
Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Parenteral
01

Overview

miR-25 lentiviral vector is a gene therapy tool designed to overexpress microRNA-25 (miR-25) within target cells. In research concerning Acute Myeloid Leukemia (AML), miR-25 has been identified as a component of the miR-106b-25 cluster that contributes to chemoresistance and the evasion of apoptosis. The vector functions by delivering the miR-25 sequence, which subsequently targets and downregulates the expression of pro-apoptotic factors, specifically BAK1 and Caspase-7. This tool is primarily utilized in preclinical studies to model the oncogenic effects of miR-25 and to evaluate its impact on drug sensitivity in leukemic cell lines and xenograft models.

Other names
lentiviral miR-25miR-25 overexpression vectormiR25 overexpression vectormiR 25 overexpression vectormiR-25 lentivirusmiR25 lentivirusmiR 25 lentivirus
02

Targets

CASP7 (Caspase-7)BAK

Beyond the preview

Go deeper on miR-25 lentiviral vector.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on miR-25 lentiviral vector.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call